美国PDS Biotechnology  
PDS Biotechnology Corporation 是一家非上市生物技术公司，致力于通过利用带阳电荷的特殊合成脂质中新发现的属性来推广新一代免疫疗法和疫苗。专有的 Versamune™ 平台纳米技术，一旦与具体癌症相关的分子相结合，经证实与临床前癌症模式中的领先临床辅助治疗相比，可实现更高的肿瘤衰退率（Cancer Immunology Immunotherapy, 2008, 57: (4) 517-530）。Versamune™ 纳米技术在开发新一代免疫疗法方面实现了巨大了进步。PDS Biotechnology Corporation 正在开发治疗子宫癌、头颈癌和黑瘤等多发癌症的主打产品。该技术还被用于开发预防流行病的疫苗。

PDS Biotechnology Corporation is a privately held biotechnology company founded to exploit the newly discovered properties of specific synthetic positively charged (cationic) lipids to commercialize a new generation of immunotherapies and vaccines. The proprietary Versamune™ platform nanotechnology, when combined with specific cancer-associated molecules, has been demonstrated to lead to increased tumor regression rates compared to leading clinical adjuvants in pre-clinical cancer models (Cancer Immunology Immunotherapy, 2008, 57: (4) 517-530). The Versamune™ nanotechnology presents a giant step forward in the development of the next generation of immunotherapies. PDS Biotechnology Corporation's lead products are being developed to treat prevalent cancers such as cervical cancer, head and neck cancer and melanoma. The technology is also being applied to the development of vaccines which are designed to protect against pandemic diseases.